Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...
Unsurprisingly, obese individuals (BMI 30-34.9 kg/m 2) had the highest prevalence of EVAF (88%) in the study, followed by class II obese PWH (BMI 35-40 kg/m 2; 69%). However, EVAF was still present in ...
The Ministry of Health has assured Kenyans that the country’s HIV response will remain on track despite disruptions caused by ...
Funding cuts have disrupted HIV prevention, treatment, and care programmes, putting PLHIV at higher risk of infections and ...
13h
UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...
HIV incidence in sub-Saharan Africa has declined substantially, according to both UNAIDS estimates and empirical data pulled ...
Researchers from Imperial College London, working with the University of Oxford and Rockefeller University, have shown ...
Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...
The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...
SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback